Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic designed to identify patients with platinum-resistant ovarian cancer who may be eligible for…
Ovarian cancer is a serious gynecological cancer with no reliable screening test, resulting in limited treatment options and a low number of survivors. Each year about 3,100 Canadians receive a…
When ovarian cancer returns and becomes resistant to platinum-based treatments, patients face one of oncology's most difficult scenarios. As reported by Drugs.com, a new therapeutic approach is changing this reality.…
CAR-NKT cell therapy (NKT) is capable of precision targeting when equipped with CAR. The UCLA study’s co-senior author, Dr. Lili Yang stated that personalized immunotherapies in use today may cost…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Currently, neoadjuvant chemotherapy is a key approach in treating ovarian cancer. Neoadjuvant chemotherapy aims to reduce tumor size, allowing for surgical removal following three cycles of chemotherapy. Additional chemotherapy…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
